Von Hippel-Lindau (VHL) disease–associated renal cell carcinoma (RCC) has always been difficult to treat. However, a group of researchers led by Dr William G. Kaelin Jr from the Dana-Faber Cancer Institute and Harvard Medical School in America have discovered treatments including immunotherapy, HIF-2α inhibitors, and potentially CDK4/6 inhibitors for the treatment of VHL-associated RCC. He […]
A protein called γ-glutamyltransferase can predict survival in patients with local and metastatic renal cell carcinoma (RCC); however, in patients treated with immune checkpoint inhibitors, such as nivolumab, this predictive role is unknown. A study to be published in the International Journal of Clinical Oncology aimed to investigate the role of γ-glutamyltransferase as a predictive […]
In this study, two doses of cabozantinib were tested in combination with atezolizumab for untreated advanced renal cell carcinoma (RCC). Cabozantinib is a vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI), while atezolizumab is an immune checkpoint inhibitor. Two doses of cabozantinib were tested; 40 mg and 60 mg. The data were fairly comparable […]
In this phase 2 clinical trial, a combination of everolimus plus bevacizumab was looked at in 37 patients with papillary renal cell carcinoma (RCC). The study showed that the combination was effective and delayed progression of the disease (progression-free survival) on average for 13.7 months. There was a response rate of 35%, and overall survival […]
A paper published in The Lancet Oncology this month provides further follow-up data from the KEYNOTE-426 study, which shows superior efficacy of pembrolizumab plus axitinib over sunitinib in patients with untreated advanced renal cell carcinoma (RCC). Eight hundred and sixty one (861) patients were randomly assigned to receive pembrolizumab plus axitinib (432) or sunitinib (429). […]
The Sottish Medicine Consortium (SMC) have issued a final decision to recommend the avelumab plus axitinib combination for untreated advanced kidney cancer for patients in Scotland. We are delighted that as from today, kidney cancer patients in Scotland can get NHS funding for avelumab in combination with axitinib for the first-line treatment of patients with advanced or metastatic renal cell carcinoma […]
Cabozantinib and sunitinib are both drugs that block the development of blood vessels to supply the tumour and are called vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors (TKIs). These drugs are used to treat patients with advanced kidney cancer. Clinical trials have shown that cabozantinib is better at extending survival than sunitinib, giving patients […]
Tivozanib is a drug that blocks the blood supply to tumours (a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor, TKI), and has been shown to be effective and safe in patients with advanced renal cell carcinoma (RCC) when used alone. This study reports the final results from phase 1b/2 clinical trial of tivozanib […]
In this retrospective study published in Cancer Reports the association between TKI-induced high blood pressure (hypertension) and treatment outcomes was reported. Fifty-two (52) patients with metastatic renal cell carcinoma (RCC) treated with first-line sunitinib, pazopanib, sorafenib, axitinib, or cabozantinib were examined for any association between TKI-induced hypertension and treatment outcomes. The study found that patients […]
A recent study coming out of China has identified a new oral tyrosine kinase inhibitor (TKI) with promising safety and efficacy for metastatic renal cell carcinoma (RCC). Anti-angiogenic treatments, such as the TKIs sunitinib, pazopanib and axitinib, play an important role in the treatment of metastatic RCC. A new TKI called apatinib targets the vascular […]
Copyright 2017 Kidney Cancer Support Network- Douglass Digital | Cambridge Web Design
